Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 1/20 | 0.60 |
| ▸ | FABP3 | P05413 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.52 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16864118 | 0.94 | SELP (0.70) | SELPFABP3NR5A2NR5A1LPAR3 | |
| SCHEMBL17484940 | 0.92 | SELP (0.72) | SELPFABP3NR5A2NR5A1LPAR3 | |
| SCHEMBL17482424 | 0.91 | SELP (0.56) | SELPFABP3NR5A2NR5A1LPAR3 | |
| SCHEMBL31275957 | 0.87 | SELP (0.67) | SELPFABP3NR5A2NR5A1LPAR3 | |
| SCHEMBL32682817 | 0.87 | SELP (0.67) | SELPFABP3NR5A2NR5A1LPAR3 | |
| SCHEMBL2125470 | 0.87 | SELP (0.67) | SELPFABP3NR5A2NR5A1LPAR3 | |
| SCHEMBL30621402 | 0.87 | SELP (0.67) | SELPFABP3NR5A2NR5A1LPAR3 | |
| SCHEMBL31429518 | 0.87 | SELP (0.67) | SELPFABP3NR5A2NR5A1LPAR3 | |
| SCHEMBL2123827 | 0.87 | SELP (0.67) | SELPFABP3NR5A2NR5A1LPAR3 | |
| SCHEMBL2123623 | 0.87 | LPAR1 (0.60) | SELPNR5A2NR5A1LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20230330260-A1 | RNA FORMULATIONS | ModemaTX, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11786607-B2 | RNA formulations | MODERNATX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-11649461-B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | MODERNATX, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | SELP 401/4885FABP3 363/4885NR5A2 3242/4885 |
| US-11786607-B2 | RNA formulations | SYNCRIP, NSUN3, RNMT | SELP 2436/4885FABP3 68/4885NR5A2 3717/4885 |
| US-20230330260-A1 | RNA FORMULATIONS | SYNCRIP, NSUN3, RNMT | SELP 2436/4885FABP3 68/4885NR5A2 3717/4885 |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | SELP 101/4885FABP3 407/4885NR5A2 2295/4885 |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | GBA1, GAA, GLA | SELP 678/4885FABP3 197/4885NR5A2 4616/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | SELP 681/4885FABP3 18/4885NR5A2 4295/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | SELP 681/4885FABP3 18/4885NR5A2 4295/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | SELP 753/4885FABP3 561/4885NR5A2 1617/4885 |
| US-11649461-B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | GBA1, GAA, GLA | SELP 697/4885FABP3 198/4885NR5A2 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.